AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home iLIVER Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine

Fumin Wanga,1Nan Zhanga,1Xiaoning WuaWei ZhangaQiang LuaRongqian WuaXu-Feng ZhangaHui GuobYi Lva( )
Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affliated Hospital of Xi'an Jiaotong University, Xi'an, China
Department of Medical Oncology, The First Affliated Hospital of Xi'an Jiaotong University, Xi'an, China

1 These authors contributed equally to this work.

Show Author Information

Abstract

Background

In clinical datasets, the characteristics of an individual patient vary so much that data loss becomes a normal event, which may be a unignorable dilemma in clinical data analysis. Therefore, the construction of a machine learning model aimed at missing clinical datasets (MCD) is of great clinical importance.

Methods

All included patients were divided into two groups according to outcome within a period of up to 36 months or less. The following characteristics (variables) were collected: age, sex, Child–Pugh status, hepatitis status, cirrhosis status, treatment, tumor size, portal vein tumor thrombus, and alpha fetoprotein (μg/mL), and a missing dataset-independent support vector machine (MDI-SVM) independent of missing data was built for the analysis.

Results

A MCD-independent SVM was developed based on clinical data from 1334 patients with hepatocellular carcinoma (HCC) at a single center, which had an accuracy of 84.43% in the survival analysis in the presence of 5% missing data. Based on the different combinations of features, our model calculated five features (tumor size, age, treatment, hepatitis status, and alpha fetoprotein) that had the greatest impact on survival in patients with HCC and extracted their weighting factors.

Conclusions

A MCD-independent SVM was developed to achieve prognosis prediction for patients with HCC in the absence of first-visit data.

References

[1]

Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380(15): 1450–62.

[2]

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127): 1301–14.

[3]

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(2): 477–491 e1.

[4]

Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16(10): 589–604.

[5]

Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014;28(5): 783–93.

[6]

Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multiinstitutional study. EBioMedicine 2019;50: 156–65.

[7]

Saillard C, Schmauch B, Laifa O, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides. Hepatology 2020; 72(6): 2000–13.

[8]

Shi JY, Wang X, Ding GY, et al. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut 2021;70(5): 951–61.

[9]

Llovet CB JM, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3): 329–38.

[10]

Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30(1): 61–74.

[11]

Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4(Suppl 3): S74–9.

[12]

Han KH, Kudo M, Ye SL, et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81(Suppl 1): 158–64.

[13]

Huo TI, Wu JC, Lee SD. Comparison of staging systems for HCC: one more positive answer or mission impossible? Hepatology 2005;42(1): 238–9.

[14]

de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol 2012;56: S75–87.

[15]

Zhou L, Wang SB, Chen SG, et al. Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab 2018;64(10): 1739–47.

[16]

Tarao K, Rino Y, Takemiya S, et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology 2000; 43(1): 20–6.

[17]

Wang ZX, Jiang CP, Cao Y, et al. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2015;14(2): 178–85.

iLIVER
Pages 154-158
Cite this article:
Wang F, Zhang N, Wu X, et al. Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine. iLIVER, 2022, 1(3): 154-158. https://doi.org/10.1016/j.iliver.2022.07.003

370

Views

1

Crossref

Altmetrics

Received: 09 April 2022
Revised: 30 June 2022
Accepted: 14 July 2022
Published: 24 August 2022
© 2022 The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return